Various investigations have shown that hepatic function is associated with prognosis in patients treated with systemic therapy, however neo‐GPS which is a combination of ALBI grade and CRP, an inflammatory marker related to the progression of cancer, is thought to have the utility in comprehensively monitoring the clinical course of HCC. The gene discussed is CRP; the disease is cancer.